Biomarkers for early intervention in Parkinson disease

帕金森病早期干预的生物标志物

• 批准号: 8473513
• 负责人: CLEMENS R SCHERZER
• 金额: $ 52万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8473513
• 关键词: Accounting; Antisense RNA; Bioenergetics; Biological Markers; Blood Circulation; Brain; Case-Control Studies; Cerebrospinal Fluid; Clinical Trials; Code; Collection; Data Set; Development; Diagnosis; Disabled Persons; Disease; Early Diagnosis; Early treatment; Epigenetic Process; Functional RNA; Future; Gene Expression; Gene Expression Profile; Genetic Variation; Health; Human; Individual; Knowledge; Lasers; Link; Measures; Motor; Movement; National Institute of Neurological Disorders and Stroke; Neurons; Onset of illness; Parkinson Disease; Participant; Pathogenesis; Pathology; Patient Care; Patients; Pharmaceutical Preparations; Phase II Clinical Trials; Physiology; Process; Proteins; Public Health; RNA; Research Infrastructure; Research Personnel; Shapes; Symptoms; Therapeutic; Time; Translating; Translations; Validation; base; biobank; clinical phenotype; cost; digital; disorder control; dopaminergic neuron; handicapping condition; innovation; neuropathology; novel; prevent; programs; public-private partnership; reconstruction; safety testing; therapy design

DESCRIPTION (provided by applicant): No cures exist, but the number of Parkinson's patients is expected to nearly double to 9.3 million in 2030. Two roadblocks impede progress on disease-modifying therapeutics. Current clinical trials are handicapped by late diagnosis, relying on impaired movements that occur when underlying neuropathology has far advanced. Moreover, in phase II clinical trials, testing safety and tolerability of a compound is straightforward, but drug effects on the underlying disease processes cannot be detected by current symptom-based measures. Here we propose a specific and a general strategy to overcome these roadblocks. More than 90,000 non-protein coding, regulatory RNAs may account for the complexity of the human brain in health and disease. Thousands of these previously hidden RNAs abound in dopaminergic neurons and regulate Parkinson's gene expression and bioenergetics processes involved in the disease onset. Regulatory RNAs integrate environmental, epigenetic, and genetic variation and directly reflect altered physiology without translation into protein. This offers a potentially ground breaking opportunity for biomarker development. Initially, we will systematically delineate all non-coding RNAs associated with incipient Parkinson's neuropathology in dopamine neurons laser-captured from 100 human brains using massively parallel sequencing and unlimited transcriptome reconstruction. Then, we will translate regulatory RNAs linked to the earliest neuropathological processes into digital biomarkers detectable in bloodstream and cerebrospinal fluid of 242 and 167 subjects, respectively. To build a generally useful express lane for biomarker development we propose a Harvard-NINDS partnership. It will leverage an unparalleled infrastructure and deliver a longitudinal Parkinson's biobank -- a catalytic, open platform for jump-starting the discovery and validation of PD biomarkers. Ancillary cerebrospinal fluid collection will be performed in the Harvard NeuroDiscovery Center Biomarker Study, a longitudinal, case-control study that already tracks clinical phenotypes and linked biospecimens of >1,886 individuals with Parkinson's disease and controls. This study will discover and translate viable biomarkers for the early detection of Parkinson's disease processes and contribute to a generally useful express lane for biomarkers development. PUBLIC HEALTH RELEVANCE: No cures exist, but the number of Parkinson's patients is expected to nearly double to 9.3 million in 2030 posing an increasing threat to public health with annual costs estimated at $10.8 billion in the US alone. We propose a specific and a general strategy to overcome two critical roadblocks that impede progress on developing disease-modifying therapeutics.

描述（由申请人提供）：没有治愈方法，但帕金森病患者的数量预计将在2030年增加近一倍，达到930万。两个障碍阻碍了疾病修饰疗法的进展。目前的临床试验由于诊断较晚而受到阻碍，依赖于潜在神经病理学已经严重发展时发生的受损运动。此外，在II期临床试验中，测试化合物的安全性和耐受性是简单的，但药物对潜在疾病过程的影响无法通过目前基于药物的措施来检测。 在这里，我们提出了一个具体的和一般性的战略，以克服这些障碍。超过90，000种非蛋白质编码的调节RNA可能解释了人类大脑在健康和疾病中的复杂性。这些先前隐藏的RNA中的数千个在多巴胺能神经元中大量存在，并调节帕金森病的基因表达和疾病发作所涉及的生物能量学过程。调控RNA整合了环境、表观遗传和遗传变异，直接反映了生理学的改变，而不翻译成蛋白质。这为生物标志物的开发提供了一个潜在的突破性机会。 最初，我们将系统地描绘所有非编码RNA与早期帕金森氏症的神经病理学在多巴胺神经元激光捕获100人脑使用大规模并行测序和无限的转录组重建。然后，我们将把与最早的神经病理过程相关的调控RNA分别翻译成242名和167名受试者的血流和脑脊液中可检测到的数字生物标志物。为了建立一个普遍有用的快速通道生物标志物的发展，我们提出了哈佛NINDS的合作伙伴关系。它将利用无与伦比的基础设施，并提供纵向帕金森氏症生物库-一个催化性的开放平台，用于启动PD生物标志物的发现和验证。辅助脑脊液收集将在哈佛神经发现中心生物标志物研究中进行，这是一项纵向病例对照研究，已经跟踪了> 1，886名帕金森病患者和对照组的临床表型和相关生物标本。这项研究将发现和翻译可行的生物标志物，用于早期检测帕金森病的过程，并有助于生物标志物开发的一般有用的快车道。 公共卫生相关性：目前还没有治愈方法，但预计到2030年，帕金森病患者的数量将增加近一倍，达到930万人，对公共卫生构成越来越大的威胁，仅在美国，每年的费用估计就达108亿美元。我们提出了一个具体的和一般的战略，以克服两个关键的路障，阻碍发展疾病修饰疗法的进展。